Sector News

Raptor Pharma (RPTP) Appoints New SVP, Gen. Counsel

July 16, 2015
Life sciences
Raptor Pharma announced the appointment of Ashley Gould, J.D. as its Senior Vice President, General Counsel and Corporate Governance. In addition, Ted Daley, Chief Business Officer, will be leaving the company at the end of September to pursue other interests.
 
“I am delighted to welcome Ashley to Raptor’s executive team,” said Julie Anne Smith, President and CEO of Raptor Pharmaceutical. “She has highly relevant expertise in biopharma spanning regulatory, quality assurance, governmental, and legal in addition to other functions. As Raptor continues to grow, I am confident she will prove an excellent strategic addition and I look forward to her counsel. Separately, I would like to thank Ted for all of the contributions he has made to Raptor’s success over the years. His involvement across all functions has been invaluable as we’ve grown into a commercial, global organization. On behalf of the Board and other members of the executive team, we wish him well in his future endeavors.”
 
Most recently Ms. Gould served as Senior Vice President, Governmental Affairs and Chief Legal and Compliance Officer for Hyperion Therapeutics. Before that, she held a number of positions of increasing responsibility at 23andMe, culminating in her appointment as Vice President, Corporate Development and Chief Legal Officer. Previously she was Vice President, Legal Affairs at CoTherix, where she worked on the company’s acquisition by Actelion, and an associate at the law firms of O’Melveny & Myers and Wilson Sonsini Goodrich & Rosati. Ms. Gould received a B.S. in Political Economy of Natural Resources from University of California, Berkeley and a J.D. from the University of San Francisco School of Law.
 
Source: Raptor

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.